PRESS RELEASE
                                                          FOR IMMEDIATE RELEASE


           New Appointments also to AEterna Scientific Advisory Board
                        and to Atrium Board of Directors

QUEBEC CITY, QUEBEC, APRIL 10, 2002 - Dr. Eric Dupont, Chairman and Chief
Executive Officer of AEterna Laboratories Inc. (TSE: AEL; Nasdaq: AELA), today
announced the appointment of Mr. Gilles Gagnon as President of the company. In
addition to assuming his new functions, Mr. Gagnon will continue as Chief
Operating Officer and will also be a member of AEterna's Board of Directors.

Dr. Dupont also announced that Dr. Claude Hariton, AEterna's Vice President,
Clinical and Regulatory Affairs, has been appointed Chief Medical Officer
(C.M.O.) of AEterna Laboratories.

"The company has reached a level of maturity where I can now delegate a number
of tasks to other management members," said Dr. Dupont. "Gilles Gagnon is a
seasoned executive with the experience and expertise needed to ensure smooth
functioning of the company's business, while simultaneously continuing to
maintain relations with present and future pharmaceutical partners. Under
Dr. Hariton's management, our clinical trials have been established at an
international level, and our product, Neovastat, has entered the final phase of
its clinical development. Henceforth, Dr. Hariton will oversee the management of
our future clinical projects," stated Dr. Dupont. "While still assuming my role
as both Chairman and Chief Executive Officer of AEterna, this new corporate
structure will enable me to invest all my energy in our acquisition plan that
will turn AEterna into a powerhouse in the development of multiple innovative
cancer therapies, at the international level."


Finally, Dr. Dupont announced the appointment of Lee S. Rosen, M.D., as a member
of AEterna's Scientific Advisory Board. Dr. Rosen is an assistant professor in
the Division of Hematology-Oncology, Department of Medicine at the University of
California, Los Angeles (UCLA). He is also the Director of the Novel
Therapeutics Cancer Program at UCLA's Jonsson Comprehensive Cancer Center.
"Thanks to his expertise, Dr. Rosen will be a valuable addition to the team,"
explained Dr. Dupont. "I am convinced that, together with the other
international clinical experts on the Scientific Advisory Board, he will
contribute to the attainment of our development objectives in oncology."


Dr. Pierre Laurin, Chairman of the Board of Atrium Biotechnologies, today
announced the election of Mr. Alain Bouchard as a member of Atrium's Board of
Directors. Mr. Bouchard is currently Chairman of the Board, President and Chief
Executive Officer of Alimentation Couche-Tard.

"We are proud to welcome Mr. Bouchard, an entrepreneur of vision and experience,
to our board. He deserves a lot of credit for the current success of
Alimentation Couche-Tard," declared Dr. Laurin. "The acquisition of the French
company Unipex, last July, was only the first step in Atrium's growth strategy,
which revolves around acquisitions. With his vast business experience,
Mr. Bouchard will undoubtedly play an important role as our company continues to
expand in the world marketplace."


Mr. Gagnon holds Masters degrees in Pharmacology (M.Sc.) and Business
Administration (M.B.A.) from the Universite de Sherbrooke. He has worked for the
past 20 years in healthcare-related organizations where he held several senior
executive positions in the hospital environment and in the pharmaceutical
industry. Prior to joining AEterna in 1999, Mr. Gagnon was Vice President,
External Affairs for Novartis Pharma Canada Inc.


Dr. Hariton received his Ph.D. in Neurosciences in France. He also graduated in
Pharmacology and in Human Biology. He was awarded Fellow from the French Medical
Research Foundation and conducted postdoctoral researches at the Neurochemistry
Center in Strasbourg, and at the French National Medical Research Institute in
Paris. He is also coauthor of approximately 80 scientific articles and papers.

Over the past 15 years, Dr. Hariton has held several senior management positions
within pharmaceutical companies including A.H. Robbins, American Home Products
and Ciba Vision Ophthalmics. Before joining AEterna Laboratories, Dr. Hariton
was Director of Neurological Therapies and Clinical and Regulatory Affairs at
Novartis Pharma's head office in Switzerland. He joined AEterna Laboratories in
1999, as Vice President, Regulatory Affairs.


Dr. Rosen is an assistant professor in the Division of Hematology-Oncology,
Department of Medicine at the University of California, Los Angeles (UCLA). He
is also the Director of the Novel Therapeutics Cancer Program at UCLA's Jonsson
Comprehensive Cancer Center. The principal investigator of many clinical trials,
Dr. Rosen is involved in translational projects with angiogenesis inhibitors,
signal transduction inhibitors and new drug combinations.

Dr. Rosen received a Masters in Public Policy from Harvard's John F. Kennedy
School of Government, and his M.D. from Baylor College of Medicine in
Houston, Texas.


Mr. Bouchard is Chairman of the Board, President and Chief Executive Officer of
Alimentation Couche-Tard Inc. and founder of the commercial enterprises which
became Alimentation Couche-Tard. This company, specialized in the multiservice
store sector, started its operations in 1980 with the opening of its first
store. Shares of Alimentation Couche-Tard started trading on the Montreal Stock
Echange (ME) in 1986. Some 13,000 employees work at its head-office and
throughout its entire network of over 1,900 multiservice stores with annual
sales in excess of $2.4 billion.

He is a member of the Boards of Directors of Quebecor Inc. and Rona Inc.


Atrium Biotechnologies is a subsidiary company 64% owned by AEterna Laboratories
Inc. It is a leading company specializing in the development and marketing of
innovative ingredients in the fields of cosmetics, nutrition, fine chemical and

Other shareholders include the Societe generale de financement, which, through
SGF Soquia, holds 24%, and the Fonds de solidarite FTQ, which holds 12%.


AEterna Laboratories Inc. is a Canadian biopharmaceutical company, and is one of
the world leaders in the development of angiogenesis inhibitors, primarily
in oncology.

Neovastat is currently undergoing two Phase III pivotal clinical trials for the
treatment of lung and kidney cancer, and one Phase II trial for treatment of
multiple myeloma, a form of blood cancer. These clinical trials are currently
being held in more than 140 clinical institutions in Canada, the U.S. and
several European countries.

AEterna shares are listed on the Toronto Stock Exchange (AEL) and
the Nasdaq (AELA).

News releases and additional information about AEterna are available on its
Web site at www.aeterna.com.

                                      -30 -

Media Relations:                            Investor Relations:
Paul Burroughs                              Jacques Raymond
Tel.: (418) 652-8525 ext. 406               Tel.: (418) 652-8525 ext. 360
Fax: (418) 577-7700                         Fax: (418) 577-7700
E-mail: paul.burroughs@aeterna.com          E-mail: jacques.raymond@aeterna.com

The Investor Relations Group
Lisa Lindberg
Tel.: (212) 825-3210
Fax: (212) 825-3229
E-mail: TheProTeam@aol.com